A review of NeuroAiDTM II (MLC901) development in Alzheimer’s disease treatment: promises of a multimodal pathway
Background: Alzheimer’s disease (AD) is a clinical and economic burden on society. Without new treatment, the impact of AD on society could triple by 2050. Aim: After a brief overview of treatments and challenges of new drug developments for AD, we reviewed the preclinical and clinical development...
Main Authors: | Dib, Michel, Ampil, Encarnita, Kee, Hoo Fan, Krespi, Yakup, Al Mahdawi, Akram, Ogun, Shamsideen Abayomi, Pakdaman, Hossein, Rejdak, Konrad |
---|---|
Format: | Article |
Published: |
Scientific Research and Community Ltd
2022
|
Similar Items
-
NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
by: Abdul Rashid, Anna Misya’il, et al.
Published: (2021) -
The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)
by: Chen, Christopher L.H., et al.
Published: (2017) -
Memandiri Usahawan Berstatus Asnaf Melalui Model MLC
by: Abd Halim, Mohammad Naim, et al.
Published: (2022) -
Jia Yong, pelajar pertama UPM juarai pertandingan MLC kebangsaan
by: Karam Singh, Daljit Singh
Published: (2019) -
9.01 Neuroscience and Behavior, Fall 2001
by: Schneider, Gerald E.
Published: (2001)